EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Prediction of lacosamide concentrations to support dose optimization during pregnancy

Jessica M Barry iD, Sílvia M Illamola, Page B Pennell, Catherine M Sherwin, Kimford J Meador iD, Angela K Birnbaum

Epilepsia · 2025

DOI: 10.1111/epi.18184 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Epilepsia, 2025. Verfasst von Jessica M Barry und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Lacosamide, Anticonvulsants, Epilepsy, Acetamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, Clinical and Translational Science Institute, University of Minnesota.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We aimed to quantify and predict lacosamide exposure during pregnancy by developing a pregnancy physiologically‐based pharmacokinetic model, allowing the prediction of potential dose increases to support maintaining a patient's preconception lacosamide concentrations.

Methods

Models for nonpregnant adults and pregnant female patients were constructed using physiochemical and pharmacological parameters identified from literature review. Evaluation of plasma concentration data from human males was digitized from the literature. Concentration data in nonpregnant and pregnant human females were available from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study, a longitudinal observational study which followed 11 nonpregnant and 16 pregnant women receiving lacosamide. Evaluation was conducted qualitatively with visual overlay (>80% of observed concentrations within 90% confidence interval) and quantitatively with average fold error and absolute average fold error (0.8–1.25 ratio acceptance criteria). Simulations of intensively‐sampled dosing regimens at steady‐state dosing across multiple gestational ages were conducted in Simcyp to evaluate the potential changes in lacosamide pharmacokinetics during pregnancy. Additional simulations were performed to explore the effects of cytochrome polymorphisms and glomerular filtration rate variability.

Results

The model adequately described the evaluation data in nonpregnant adults and pregnant adults between 10 and 40 weeks of gestation. Estimates in patients at 40‐ weeks of gestation indicated that lacosamide clearance increased by 48.2% compared to nonpregnant patients. Maximum lacosamide concentration (Cmax) during a simulated dosing interval also fell by 30% from preconception to 40 weeks. A simulated dose increase of 50 mg once daily at 10 weeks of gestation supported maintenance of preconception concentration for a typical patient taking the most common dosing regimen of 200 mg, twice daily (BID), preconception. Significance Simulated changes in lacosamide concentration align with the limited data available in observational studies. Our simulations support the use of therapeutic drug monitoring and dose adjustments to maintain the efficacy of lacosamide pharmacotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LacosamideAnticonvulsantsEpilepsyAcetamidesPregnancy ComplicationsHumansFemalePregnancyAdultMaleDose-Response Relationship, DrugLongitudinal StudiesYoung AdultModels, Biological

Stichwörter der Autor:innen

dose optimizationlacosamidephysiologically‐based pharmacokinetic monitoringpregnancytherapeutic drug monitoring

Substanzen

LacosamideAnticonvulsantsAcetamides

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Differentia Bio, South San Francisco, California, USA.
  • Internal Medicine, UWA Medical School, The University of Western Australia, Perth, Western Australia, Australia.
  • Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.

ORCID-Profile: Jessica M Barry, Kimford J Meador

Förderung

  • NINDS NIH HHS
  • NCATS NIH HHS
  • Clinical and Translational Science Institute, University of Minnesota
  • NICHD NIH HHS
  • National Institute of Child Health and Human Development
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Barry, J. M., Illamola, S. M., Pennell, P. B., Sherwin, C. M., Meador, K. J., & Birnbaum, A. K. (2025). Prediction of lacosamide concentrations to support dose optimization during pregnancy. Epilepsia. https://doi.org/10.1111/epi.18184

Vancouver

Barry JM, Illamola SM, Pennell PB, Sherwin CM, Meador KJ, Birnbaum AK. Prediction of lacosamide concentrations to support dose optimization during pregnancy. Epilepsia. 2025. doi:10.1111/epi.18184

BibTeX
@article{Barry2025,
  author = {Barry, Jessica M and Illamola, Sílvia M and Pennell, Page B and Sherwin, Catherine M and Meador, Kimford J and Birnbaum, Angela K},
  title = {Prediction of lacosamide concentrations to support dose optimization during pregnancy},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18184}
}
Kostenlos starten →